Related Experiment Video

Updated: May 13, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Genome-wide analyses of sarcoma: implications for future treatment options

Joshua D Schiffman

    Future Oncology (London, England)
    |March 9, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
    09:33

    Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

    Published on: August 25, 2023

    Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
    09:21

    Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

    Published on: September 13, 2019

    Related Experiment Videos

    Last Updated: May 13, 2026

    The In ovo CAM-assay as a Xenograft Model for Sarcoma
    12:44

    The In ovo CAM-assay as a Xenograft Model for Sarcoma

    Published on: July 17, 2013

    Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
    09:33

    Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

    Published on: August 25, 2023

    Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
    09:21

    Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

    Published on: September 13, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Neutrophil extracellular traps offer a new therapeutic target for elephant endotheliotropic herpes virus-hemorrhagic disease (EEHV-HD).

    Communications biology·2026

    Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk.

    medRxiv : the preprint server for health sciences·2026

    Immune-cancer analyses across mammals reveal a potential trophic level and platelet-linked tradeoff between cancer and trauma mortality.

    bioRxiv : the preprint server for biology·2026

    Evidence for improved DNA repair in the long-lived bowhead whale.

    Nature·2025

    Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers.

    Nature communications·2025

    Advancing cancer research via comparative oncology.

    Nature reviews. Cancer·2025

    Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

    Future oncology (London, England)·2026

    Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.

    Future oncology (London, England)·2026

    A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

    Future oncology (London, England)·2026

    Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.

    Future oncology (London, England)·2026

    TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.

    Future oncology (London, England)·2026

    Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.

    Future oncology (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us